Oncology Medical News about Hematopoietic Stem Cell Transplantation Hematopoietic Stem Cells

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

High-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies
Bone Marrow Transplantation, 10/01/09

Kwong Y–L – Autologous HSCT may not be necessary for good–risk patients in CR. Whether poor risk patients will have improved outcome with autologous HSCT remains to be defined. The role of allogeneic HSCT requires more rigorous future studies.

Exclusive Author Commentary
Y-L Kwong, 10/01/09

Natural killer cell malignancies are classified as extranodal NK/T cell lymphoma, nasal type, and aggressive NK cell leukemia in the current WHO classification. It is a disease predominantly found in Asian and South American populations, although occasional cases have now been reported from Western patients. Although it is traditionally viewed as an aggressive lymphoma, early stage disease in fact has a favorably prognosis. Haematopoietic stem cell transplantation therefore is not indicated for such patients in first complete remission. Even for patients with localized relapse, salvage chemotherapy and radiotherapy is also effective. However, for patients with advanced disease (stage III, IV) and the leukemic form of the disease, treatment results are unsatisfactory. Unfortunately, autologous haematopoietic stem cell transplantation has not been shown to be beneficial to these patients. Allogeneic haematopoietic stem cell transplantation may be the best option. The number of patients treated by this modality is small, and its efficacy remains to be defined by prospective clinical trials.

<< Previous
Stereotactic body radiation therapy for liver metastases

Next >>
Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in...

Preemptive Management of Epstein-Barr Virus Reactivation After Hematopoietic Stem-Cell Transplantation
Transplantation, 10/29/09 Relevance Score: 98%

History of cord blood transplantation
Bone Marrow Transplantation, 10/07/09 Relevance Score: 98%

Pediatric related and unrelated cord blood transplantation for malignant diseases
Bone Marrow Transplantation, 10/07/09 Relevance Score: 98%

Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD)
Bone Marrow Transplantation, 10/01/09 Relevance Score: 98%

Outcome of hematopoietic cell transplantation in children with sickle cell disease, a single center's experience
Bone Marrow Transplantation, 10/01/09 Relevance Score: 98%